Extracorporeal membrane oxygenation (ECMO) has been associated with acceptable short‐term survival in patients with refractory respiratory failure secondary to coronavirus disease 2019 (COVID‐19) pneumonia. Previous studies have demonstrated acceptable long‐term… Click to show full abstract
Extracorporeal membrane oxygenation (ECMO) has been associated with acceptable short‐term survival in patients with refractory respiratory failure secondary to coronavirus disease 2019 (COVID‐19) pneumonia. Previous studies have demonstrated acceptable long‐term outcomes in patients supported with ECMO for respiratory failure of other etiologies. However, long‐term survival and functional outcomes in COVID ECMO patients remain unknown.
               
Click one of the above tabs to view related content.